Rezolute (RZLT) Shares Outstanding (2010 - 2026)
Rezolute (RZLT) posted Shares Outstanding (Entity) of $96.3 million for Q1 2026, up 0.78% sequentially from $95.5 million in Q4 2025, and up 59.05% YoY from $60.5 million in Q1 2025.
Analysis
Rezolute (RZLT) Shares Outstanding (2010 - 2026) Analysis & Trends
Rezolute has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $96.3 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 59.05% year-over-year to $96.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.3 million (up 59.05% YoY) and the FY2025 annual result came in at $87.0 million, up 63.39% from the prior year.
- Shares Outstanding (Entity) improved to $96.3 million in Q1 2026 per RZLT's latest filing, from $95.5 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $96.3 million in Q1 2026 and troughed at $15.6 million in Q1 2022.
- A 5-year average of $59.2 million and a median of $51.4 million in 2022 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) surged 237118.09% in 2022, then fell 1.16% in 2024.
- Over 5 years, Shares Outstanding (Entity) stood at $51.4 million in 2022, then dropped by 0.0% to $51.4 million in 2023, then climbed by 17.75% to $60.5 million in 2024, then jumped by 57.84% to $95.5 million in 2025, then rose by 0.78% to $96.3 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $96.3 million, $95.5 million, and $91.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Rezolute | 475.98 Mn | 475.98 Mn | - | 104.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 104.04 Mn |
| Dec 31, 2025 | 103.69 Mn |
| Sep 30, 2025 | 103.42 Mn |
| Jun 30, 2025 | 76.00 Mn |
| Mar 31, 2025 | 70.03 Mn |
| Dec 31, 2024 | 69.94 Mn |
| Sep 30, 2024 | 69.74 Mn |
| Jun 30, 2024 | 51.47 Mn |
| Mar 31, 2024 | 50.81 Mn |
| Dec 31, 2023 | 51.41 Mn |
| Sep 30, 2023 | 51.41 Mn |
| Jun 30, 2023 | 51.19 Mn |
| Mar 31, 2023 | 51.41 Mn |
| Dec 31, 2022 | 51.41 Mn |
| Sep 30, 2022 | 50.53 Mn |
| Jun 30, 2022 | 18.20 Mn |
| Mar 31, 2022 | 17.22 Mn |
| Dec 31, 2021 | 15.68 Mn |
| Sep 30, 2021 | 8.51 Mn |
| Jun 30, 2021 | 7.67 Mn |